NCT00673790
The Blood Pressure and Metabolic Effects of Nebivolol in Hypertensive Patients With Impaired Glucose Tolerance or Impaired Fasting Glucose
See it on ClinicalTrials.gov ↗537 people
43.9%
56.1%
236 womenmiddle line = equal numbers301 men
- Phase
- PHASE4
- Paid for by
- Forest Laboratories
- Finished
- 2010-07-09
- Health conditions
- Hypertension
- Who could join
- Anyone
- Ages
- 18 Years – 80 Years
- Average age
- mean 55.1 years
- Age 65+
- 17.5%
- Weight (BMI)
- Not reported
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- Not reported
Women left out
- No heart disease
Women with heart disease, heart rhythm problems or a past heart attack were turned away.
“Have clinically significant respiratory, liver or cardiovascular disease”
- No diabetes
Women with diabetes were turned away.
“Use of niacin or antidiabetic drugs (oral or injectable) within 6 months before study entry”
Study titles and rules are shown in their original English.